The therapeutic value of ipsilateral supraclavicular lymphadenectomy in locally advanced breast cancer: A review

Sen Li,Yingfang Shi,Zhichun Wang

DOI: https://doi.org/10.1097/md.0000000000039340

IF: 1.6

2024-08-19

Medicine

Abstract:Breast cancer is a highly heterogeneous malignant tumor, showing a gradually increasing incidence trend in our country, which seriously threatens women's health. [ 1 ] The modes of metastasis of breast cancer include local extension, blood supply metastasis and lymphatic metastasis. [ 2 ] In the lymphatic metastasis pathway, tumor cells can invade the ipsilateral axillary lymph nodes through the lateral border lymphatic vessels of the pectoralis major muscle, and then invade the subclavian lymph nodes and then the supraclavicular lymph nodes. In addition, the medial lymphatic vessels can invade the parasternal lymph nodes along the perforating branches of the internal mammary vessels, thereby invading the supraclavicular lymph nodes. [ 2 , 3 ] Clinically, the incidence of isolated ipsilateral supraclavicular lymph node metastasis (ISLM) is low, and breast cancer patients with ISLM account for about 1% to 4.3%. [ 4 , 5 ] Due to its low incidence, there has been a lack of prospective, large clinical randomized controlled trials on the choice of treatment methods for ISLM. At present, the common treatment principle is to use adjuvant systemic therapy, including chemotherapy, targeted therapy, endocrine therapy, etc, on the basis of surgical treatment of the primary tumor. Radiotherapy is the main local treatment for the supraclavicular region, and surgical treatment of local supraclavicular lymph node resection has not been recommended as the standard treatment for ISLM. Whether to perform supraclavicular lymph node dissection for ISLM patients has become a difficult choice for breast surgeons.

medicine, general & internal